# A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons

> **NCT00000743** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 64 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Alvircept sudotox
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00000743
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1995-05
- **Target enrollment:** 64 (—)
- **Last updated:** 2021-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000743, "A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00000743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*